You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 6,933,395

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,933,395

Title:	PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY
Abstract:	Process for the production of drospirenone (6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, DRSP) (1) and 7α-(3-hydroxy-1-propyl)-6β,7β; 15β,16β-dimethylene-5β-androstane-3β,5,17β-triol (ZK 92836) and 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone (ZK 90965) as intermediate products of the process.
Inventor(s):	Jörg-Thorsten Mohr, Klaus Nickisch
Assignee:	Bayer Pharma AG
Application Number:	US09/640,748
Patent Claims:	1. A composition comprising 6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, a pharmaceutically acceptable carrier, and less than 0.2% weight of said compound of contaminants 2. A composition comprising 6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, a pharmaceutically acceptable carrier, and less than 0.2% by weight of said compound of the contaminants wherein X is an anion acid which is effective to open said 6β,7β-methylene group. 3. A composition comprising 6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone made by a process comprising dehydrating a compound of Formula III, which was made by oxidizing in the presence of a ruthenium salt a compound of formula which was made by catalytically hydrogenating a compound of formula I (b) a pharmaceutically acceptable carrier, and (c) less than 0.2% by weight of said compound (a) of the by products of said preparation process which are wherein X is anion of an acid which is effective to open said 6β,7β-methylene group. 4. A composition of claim 3, wherein in said process, said dehydrating is performed after said compound of Formula III is isolated from the medium in which it is prepared. 5. 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone in isolated form. 6. 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone in isolated form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.